SPHRY (SPHRY) Stock Price & Analysis
SPHRY (SPHRY) rose 4.76% to USD 4.62 as of July 26, 2026 at 09:45 UTC, according to Nexqual real-time market data.
SPHRY last closed at USD 4.41; the session ranged USD 5.3–5.3 on volume of 26 shares. Market capitalization is $199.62M, with a 52-week range of USD 0.65–5.7 (OQX). Source: Nexqual, July 26, 2026 at 09:45 UTC.
Key Statistics (as of July 26, 2026 at 09:45 UTC)
| Price | USD 4.62 |
|---|---|
| Change | ▲ 4.76% (up) |
| Previous Close | USD 4.41 |
| Open | USD 5.3 |
| Day Range | USD 5.3 – 5.3 |
| 52-Week Range | USD 0.65 – 5.7 |
| Volume | 26 shares |
| Market Cap | $199.62M |
| Exchange | OQX |
Technical Analysis (SPHRY)
Nexqual's technical model rates SPHRY "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 26, 2026 at 09:45 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 43.41 (neutral) |
| vs SMA50 | Below (USD 4.77) |
| MACD | -0.08 (negative) |
Analyst Ratings (SPHRY)
Wall Street analysts rate SPHRY "None", per Nexqual as of July 26, 2026 at 09:45 UTC.
| Consensus Rating | None |
|---|
Earnings (SPHRY)
Source: Nexqual, July 26, 2026 at 09:45 UTC.
Financials & Fundamentals (SPHRY)
| Total Revenue | $14.58M |
|---|---|
| Revenue Growth (YoY) | +359.60% |
| Gross Margin | +29.59% |
| Operating Margin | +12.26% |
| Profit Margin | -22.16% |
| ROE | -14.47% |
| Debt / Equity | 3.68 |
| Current Ratio | 5.26 |
| Total Cash | $18.25M |
| Total Debt | $790,000 |
| Free Cash Flow | $-612,375 |
Source: Nexqual, July 26, 2026 at 09:45 UTC.
Financial Health Score (SPHRY)
Nexqual rates SPHRY's overall financial health "Mixed" across five dimensions, as of July 26, 2026 at 09:45 UTC.
| Growth | Strong — Revenue +360% YoY (latest Q) |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $18M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$852K |
| Efficiency | Critical — ROE -14%, ROA -7.2% |
Ownership (SPHRY)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 43.21M |
| Float | 29.40M |
Source: Nexqual, July 26, 2026 at 09:45 UTC.
Leadership (SPHRY)
SPHRY is led by Cheryl Maley B.Sc. (age 57), CEO, MD & Director, per Nexqual as of July 26, 2026 at 09:45 UTC.
| CEO, MD & Director | Cheryl Maley B.Sc. (age 57) |
|---|---|
| CFO & Company Secretary | Justin Cahill |
| Director of People & Culture | Miranda Sowden |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SPHRF | STARPHARMA HOLDINGS LIMITED | USD 0.55 | ▲ 0% |
| CUVL | Clinuvel Pharmaceuticals Limited American Depositary Shares | USD 6.95 | ▼ 0.71% |
| SNPHY | Santen Pharmaceutical Co., Ltd. | USD 11.65 | ▼ 8.05% |
| SPL.AX | STARPHARMA FPO [SPL] | AUD 0.69 | ▼ 0.72% |
| ACCL | Acco Group Holdings Limited | USD 2.13 | ▼ 0.47% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 09:45 UTC. This page is informational and not investment advice.